P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation

► Expression of P-glycoprotein induces loss of L1210 cells sensitivity to cisplatin. ► P-glycoprotein in L1210 cells depresses cisplatin induced caspase-3 activation. ► P-glycoprotein in L1210 cells eliminates cisplatin induced Bcl-2 suppression. ► P-glycoprotein in L1210 cells alternates cisplatin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Toxicology in vitro 2012-04, Vol.26 (3), p.435-444
Hauptverfasser: Gibalová, Lenka, Šereš, Mário, Rusnák, Andrej, Ditte, Peter, Labudová, Martina, Uhrík, Branislav, Pastorek, Jaromir, Sedlák, Ján, Breier, Albert, Sulová, Zdenka
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:► Expression of P-glycoprotein induces loss of L1210 cells sensitivity to cisplatin. ► P-glycoprotein in L1210 cells depresses cisplatin induced caspase-3 activation. ► P-glycoprotein in L1210 cells eliminates cisplatin induced Bcl-2 suppression. ► P-glycoprotein in L1210 cells alternates cisplatin induced apoptosis progression. Multidrug resistance (MDR) is a phenomenon in which cells become resistant to cytostatic drugs and other substances with diverse chemical structures and cytotoxicity mechanisms. The most often observed molecular mechanism for MDR includes high levels of P-glycoprotein (P-gp) – an ABCB1 member of the ABC drug transporter family. Overexpression of P-gp in neoplastic tissue is an obstacle to chemotherapeutic treatment. Herein, we were focused on differences in apoptosis induced by cisplatin (no substrate for P-gp) between P-gp-positive and P-gp-negative L1210 cells. P-gp-positive cells were obtained by either L1210 cell adaptation to vincristine (R) or L1210 cell transfection with the human gene for P-gp (T) and compared with parental L1210 cells (S). R and T cells were more resistant to CisPt than S cells. R and T cell resistance to CisPt-induced apoptosis could not be reversed by verapamil (a well-known P-gp inhibitor), which excludes P-gp transport activity as a cause of CisPt resistance. CisPt induced a more pronounced entry into apoptosis in S than R and T cells, which was measured using the annexin-V/propidium iodide apoptosis kit. CisPt induced more pronounced caspase-3 activation in S than R and T cells. CisPt did not induce changes in the P-gp protein level for R and T cells. While similar levels of Bax and Bcl-2 proteins were observed in P-gp-negative and P-gp-positive cells, CisPt induced a more significant decrease in Bcl-2 levels for S cells than P-gp-positive cells. Expression of p53 and its molecular chaperone Hsp90 were more pronounced in R and T than S cells. Moreover, CisPt enhanced the upregulation of p53 and Hsp90 in R and T cells to a higher degree than S cells. Apoptosis was shown to be the prevalent mode of cell death in S, R and T cells by the typical DNA fragmentation and cell ultrastructure changes. All of the above findings indicate that P-gp, independent of its drug efflux activity, induced changes in cell regulatory pathways that confer a partial loss of cisplatin sensitivity.
ISSN:0887-2333
1879-3177
DOI:10.1016/j.tiv.2012.01.014